Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The South San Francisco biotech ...

If only they were robotic! Instead, chatbots have developed a distinctive — and grating — voice. Credit...Illustration by Giacomo Gambineri Supported by By Sam Kriss In the quiet hum of our digital ...

When was the last time you found a little handwritten note in your mailbox? The feel of the paper, the art of the postage stamp, personal penmanship, and the effort associated with getting that to a ...

Big quote: Sundar Pichai now talks about vibe coding in the same breath as blogging and YouTube – not as a metaphor for hype but as evidence that software creation is slipping further out of engineers ...

In context: Microsoft is going in some very wild directions with Windows development, with Notepad being one of the most outstanding guinea pigs in AI and design experimentations. Notepad now has the ...

Soon AI agents will be writing better, cleaner code than any mere human can, just like compilers can write better assembly. There’s an old joke about the weather in San Francisco: If you don’t like it ...

Thousands of credentials, authentication keys, and configuration data impacting organizations in sensitive sectors have been sitting in publicly accessible JSON snippets submitted to the JSONFormatter ...

Journal Editorial Report: The week's best and worst from Kim Strassel, Jason Riley and Dan Henninger. A state-backed threat group, likely Chinese, crossed a threshold in September that cybersecurity ...